| abstract |
The present disclosure relates to methods and agents for enhancing the effects of T cells engineered to express a chimeric antigen receptor (CAR). These methods and agents are particularly useful in the treatment of diseases characterized by diseased cells expressing the antigen to which CAR is directed. Specifically, the present disclosure comprises providing a subject with T cells genetically modified to express a chimeric antigen receptor (CAR), and administering to the subject an IL2 or a polynucleotide encoding IL2. Regarding how to include. The methods of the present disclosure may comprise administering IL2 or a polynucleotide encoding IL2, and additional cytokines or polynucleotides encoding additional cytokines, the additional cytokine being IL7 or IL21. T cells genetically modified to express CAR are produced by administration of T cells genetically modified to express CAR or in subjects with T cells genetically modified to express CAR. By doing so, it can be provided to the subject. The methods of the present disclosure may further comprise administering to the subject an antigen or a variant thereof, or a polynucleotide encoding an antigen or variant thereof, and T cells genetically modified to express CAR target the antigen. And. In one particularly preferred embodiment, the polynucleotide administered according to the present disclosure is RNA. |